Evidence map›Paper›PMID 27829236›Full record

ArticleOncotarget2016

FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients.

Zheng Wang, Chuanbao Zhang, Lihua Sun, Jingshan Liang, Xing Liu, Guanzhang Li, Kun Yao, Wei Zhang, Tao Jiang

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.International journal of molecular sciences · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Zheng WangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Chuanbao ZhangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Lihua SunBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Jingshan LiangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Xing LiuBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Guanzhang LiBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Kun YaoSanbo Brain Hospital, Capital Medical University, Beijing, China.
Wei ZhangBeijing Tiantan Hospital, Capital Medical University, Beijing, China.
Tao JiangBeijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Institute of Neurosurgery · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundActivation of receptor tyrosine kinases is common in Malignancies. FGFR3 fusion with TACC3 has been reported to have transforming effects in primary glioblastoma and display oncogenic activity in vitro and in vivo. We set out to investigate the role of FGFR3 in glioma through transcriptomic analysis.

resultsFGFR3 increased in Classical subtype and Neural subtype consistently in CGGA and TCGA cohort. Similar patterns of FGFR3 distribution through subtypes were observed in CGGA and TCGA samples. Gene ontology analysis was performed with genes that were significantly correlated with FGFR3 expression. We found that positively associated biological processes of FGFR3 were focused on differentiated cellular functions and neuronal activities, while negatively correlated biological processes focused on mitosis and cell cycle phase. Clinical investigation showed that higher FGFR3 expression predicted improved survival for glioma patients, especially in Proneural subtype. Moreover, FGFR3 showed very limited relevance with other receptor tyrosine kinases in glioma at transcriptome level. MATERIALS AND

methodsFGFR3 expression data of glioma was obtained from Chinese Glioma Genome Atlas (CGGA) and TCGA (The Cancer Genome Atlas). In total, RNA sequencing data of 325 glioma samples and mRNA microarray data of 301 samples from CGGA dataset were enrolled into this study. To consolidate the findings that we have revealed in CGGA dataset, RNA-seq data of 672 glioma samples from TCGA dataset were used as a validation cohort. R language was used as the main tool to perform statistical analysis and graphical work.

conclusionsFGFR3 expression increased in classical and neural subtypes and was associated with differentiated cellular functions. FGFR3 showed very limited correlation with other common receptor tyrosine kinases, and predicted improved survival for glioma patients.

Indexed as

Biomarkers, TumorCohort StudiesGene Expression Regulation, NeoplasticGene OntologyGliomaHumansMicrotubule-Associated ProteinsOncogene Proteins, FusionPrognosisReceptor, Fibroblast Growth Factor, Type 3Sequence Analysis, RNASurvival AnalysisTranscriptomeUp-RegulationBiomarkers, TumorFGFR3 protein, humanMicrotubule-Associated ProteinsOncogene Proteins, FusionReceptor, Fibroblast Growth Factor, Type 3TACC3 protein, humanFGFR3FGFR-TACC fusion genesgliomareceptor tyrosine kinase

Identifiers

PMID27829236
PMCPMC5356683
OpenAlexW2547127934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.